Drug Profile
Research programme: antimicrobial peptide therapeutics - BioAMPS
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator University of British Columbia; University of Colorado at Denver
- Developer BioAMPs International
- Class Antibacterials; Antivirals; Peptide antibiotics; Peptides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Mycoses; Viral infections
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Bacterial infections in USA (Parenteral)
- 04 Sep 2023 Discontinued - Preclinical for Mycoses in USA (Parenteral)
- 04 Sep 2023 Discontinued - Preclinical for Viral infections in USA (Parenteral)